Neuropace Stock Performance
| NPCE Stock | USD 14.61 0.05 0.34% |
The company secures a Beta (Market Risk) of 1.53, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuropace will likely underperform. At this point, Neuropace has a negative expected return of -0.18%. Please make sure to verify Neuropace's kurtosis, market facilitation index, and the relationship between the semi variance and rate of daily change , to decide if Neuropace performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Neuropace has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 1.53 | Five Day Return (5.15) | Year To Date Return (4.02) | Ten Year Return (41.67) | All Time Return (41.67) |
1 | Disposition of 1338 shares by Martha Morrell of Neuropace at 16.66 subject to Rule 16b-3 | 12/03/2025 |
2 | Published on 2025-12-04 134714 - Newser | 12/04/2025 |
3 | Acquisition by Fischer Frank M of 2303 shares of Neuropace at 10.31 subject to Rule 16b-3 | 12/26/2025 |
4 | UBS sees upside for NeuroPace shares with 22 percent CAGR and market expansion drivers - MSN | 01/05/2026 |
5 | NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook | 01/13/2026 |
6 | Disposition of 1430 shares by Martha Morrell of Neuropace at 12.56 subject to Rule 16b-3 | 01/21/2026 |
7 | NeuroPace stock price target raised to 19 from 18 at H.C. Wainwright - Investing.com Nigeria | 01/27/2026 |
8 | How NeuroPace Analysts Are Quietly Rewriting The Story Behind The Stock - Yahoo Finance | 02/03/2026 |
9 | Essex Investment Management Co. LLC Raises Holdings in NeuroPace, Inc. NPCE - MarketBeat | 02/11/2026 |
10 | Disposition of 3412 shares by Martha Morrell of Neuropace at 14.34 subject to Rule 16b-3 | 02/20/2026 |
| Begin Period Cash Flow | 18.2 M | |
| Total Cashflows From Investing Activities | 9 M |
Neuropace | Build AI portfolio with Neuropace Stock |
Neuropace Relative Risk vs. Return Landscape
If you would invest 1,650 in Neuropace on November 26, 2025 and sell it today you would lose (194.00) from holding Neuropace or give up 11.76% of portfolio value over 90 days. Neuropace is currently does not generate positive expected returns and assumes 2.623% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Neuropace, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neuropace Target Price Odds to finish over Current Price
The tendency of Neuropace Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 14.61 | 90 days | 14.61 | about 89.2 |
Based on a normal probability distribution, the odds of Neuropace to move above the current price in 90 days from now is about 89.2 (This Neuropace probability density function shows the probability of Neuropace Stock to fall within a particular range of prices over 90 days) .
Neuropace Price Density |
| Price |
Predictive Modules for Neuropace
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neuropace. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuropace's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuropace Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neuropace is not an exception. The market had few large corrections towards the Neuropace's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neuropace, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neuropace within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 1.53 | |
σ | Overall volatility | 0.97 | |
Ir | Information ratio | 0.05 |
Neuropace Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neuropace for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neuropace can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neuropace generated a negative expected return over the last 90 days | |
| Neuropace has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 79.91 M. Net Loss for the year was (27.14 M) with profit before overhead, payroll, taxes, and interest of 72.83 M. | |
| Neuropace currently holds about 92.41 M in cash with (17.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Neuropace has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Disposition of 3412 shares by Martha Morrell of Neuropace at 14.34 subject to Rule 16b-3 |
Neuropace Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neuropace Stock often depends not only on the future outlook of the current and potential Neuropace's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neuropace's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.1 M | |
| Cash And Short Term Investments | 52.8 M |
Neuropace Fundamentals Growth
Neuropace Stock prices reflect investors' perceptions of the future prospects and financial health of Neuropace, and Neuropace fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuropace Stock performance.
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.1) % | ||||
| Current Valuation | 354.42 M | ||||
| Shares Outstanding | 33.31 M | ||||
| Price To Book | 17.75 X | ||||
| Price To Sales | 5.03 X | ||||
| Revenue | 79.91 M | ||||
| Gross Profit | 72.83 M | ||||
| EBITDA | (16.57 M) | ||||
| Net Income | (27.14 M) | ||||
| Cash And Equivalents | 92.41 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 73.34 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (17.95 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Market Capitalization | 477.63 M | ||||
| Total Asset | 94.65 M | ||||
| Retained Earnings | (530.95 M) | ||||
| Working Capital | 66.18 M | ||||
About Neuropace Performance
By analyzing Neuropace's fundamental ratios, stakeholders can gain valuable insights into Neuropace's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neuropace has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neuropace has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 269.76 | 273.68 | |
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (3.90) | (3.70) |
Things to note about Neuropace performance evaluation
Checking the ongoing alerts about Neuropace for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuropace help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neuropace generated a negative expected return over the last 90 days | |
| Neuropace has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 79.91 M. Net Loss for the year was (27.14 M) with profit before overhead, payroll, taxes, and interest of 72.83 M. | |
| Neuropace currently holds about 92.41 M in cash with (17.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| Neuropace has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Disposition of 3412 shares by Martha Morrell of Neuropace at 14.34 subject to Rule 16b-3 |
- Analyzing Neuropace's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuropace's stock is overvalued or undervalued compared to its peers.
- Examining Neuropace's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neuropace's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuropace's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neuropace's stock. These opinions can provide insight into Neuropace's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |